(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
The chapters of this book report cutting-edge research on molecular events in adiposity and type 2 diabetes, thus opening the way for innovative drug-based therapeutic strategies. It addresses all those who wish to keep in touch with recent developments in the field.
Contents:
Preface. Targeting type 2 diabetes. Dual acting and pan-PPAR activators as potential anti-diabetic therapies. GLP-agonists and Dipeptidyl-Peptidase IV Inhibitors. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. SGLT Inhibitors as New Therapeutic Tools in the Treatment of Diabetes. Inhibitors of 11b-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Nampt and its potential role in inflammation and type 2 diabetes. Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance. Overcoming Insulin Resistance with Ciliary Neurotrophic Factor. Thermogenesis and related metabolic targets in anti-diabetic therapy. Interleukin targeted therapy for metabolic syndrome and type 2 diabetes. Fructose-1, 6-Bisphosphatase Inhibitors for Reducing Excessive Endogenous Glucose Production in Type 2 Diabetes. AMP-activated protein kinase and metabolic control. Mitochondria as potential targets in antidiabetic therapy. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects
PRODUCT DETAILS
Publisher: Springer (Springer-Verlag Berlin and Heidelberg GmbH & Co. K)
Publication date: March, 2011
Pages: 421
Weight: 799g
Availability: Available
Subcategories: Diseases and Disorders, Endocrinology, General Issues, Pharmacology, Physiology
Publisher recommends
From the same series
